Targeting cancer lactate metabolism with synergistic combinations of synthetic catalysts and monocarboxylate transporter inhibitors.

Co-administration of a non-toxic concentration of sodium formate (0–2 mM), as a reducing agent and hydride donor, alongside catalyst 1 resulted in a highly significant enhancement of the cytotoxic potency of catalyst 1 by up to 60% towards MCF7 breast cancer cells ( p < 0.001, Fig. 2 and Supplementary Information Table S4).

also in 132,142 other papers